Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/jco.2001.19.3.602PMID 11157009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjuvant chemotherapy in stage-II breast cancer: An overview of the NSABP clinical trials

  2005cited by this paper
• Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer.

  1999cited by this paper
• Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

  1998cited by this paper
• Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.

  1998cited by this paper
• Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients.

  1998cited by this paper
• A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity.

  1998cited by this paper
• The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity.

  1998cited by this paper
• Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.

  1997cited by this paper
• Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group.

  1997cited by this paper
• Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

  1996cited by this paper
• Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.

  1996cited by this paper
• Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.

  1996cited by this paper
• Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results.

  1995cited by this paper
• Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma.

  1995cited by this paper
• Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer.

  1994cited by this paper
• Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.

  1994cited by this paper
• Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial.

  1993cited by this paper
• Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe

  1990cited by this paper
• Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience.

  1989cited by this paper
• Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.

  1987cited by this paper
• Comparison of Different Trials of Adjuvant Chemotherapy in Stage II Breast Cancer Using a Natural History Data Base

  1987cited by this paper
• Development and Use of a Natural History Data Base of Breast Cancer Studies

  1987cited by this paper
• Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy.

  1986cited by this paper
• Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer.

  1986cited by this paper
• A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy

  1978cited by this paper

• The Potential of Plant Polysaccharides and Chemotherapeutic Drug Combinations in the Suppression of Breast Cancer

  2024cites this paper
• Comparison of neoadjuvant chemotherapy response and prognosis among pegylated liposomal doxorubicin, epirubicin and pirarubicin in HR ⩽ 10%/HER2-negative breast cancer: an exploratory real-world multicentre cohort study

  2024cites this paper
• Influence of menopause on chemotherapy‐induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study

  2023cites this paper
• Absolute Lymphocyte Count Changes During Neoadjuvant Chemotherapy are Associated With Prognosis of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Patients.

  2023cites this paper
• Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review

  2022cites this paper
• Cardioprotective effect of Chinese herbal medicine for anthracycline-induced cardiotoxicity in cancer patients: A meta-analysis of prospective studies

  2022cites this paper
• Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial

  2022cites this paper
• Uridine Glucuronosyltransferase 2B7 Polymorphism-Based Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy for Early-Stage Breast Cancer.

  2021cites this paper
• [Diffusion prophylactic axillary irradiation in breast cancer - Literature review].

  2021cites this paper
• On the Impact of Premature Termination of Chemotherapy on Relapse of Breast Cancer

  2021cites this paper
• Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000–1

  2020cites this paper
• Trastuzumab

  2020cites this paper
• Homologous recombination deficiency in breast cancer: Implications for risk, cancer development, and therapy

  2020cites this paper
• Impact of Primary Pegfilgrastim Prophylaxis on Relative Dose Intensity in Neoadjuvant/Adjuvant FEC-100 Chemotherapy

  2020cites this paper
• Standard-dose epirubicin increases the pathological complete response rate in neoadjuvant chemotherapy for breast cancer: a multicenter retrospective study.

  2020cites this paper
• Adjuvant Systemic Chemotherapy for HER2-Negative Disease

  2019cites this paper
• Adjuvant Systemic Therapy in Breast Cancer

  2019cites this paper
• Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes.

  2019cites this paper
• Health-related quality of life associated with different cancer treatments in Chinese breast cancer survivors in Taiwan.

  2019cites this paper
• Visceral osteopathic manipulative treatment reduces patient reported digestive toxicities induced by adjuvant chemotherapy in breast cancer: A randomized controlled clinical study.

  2019cites this paper
• Drug Combinations in Breast Cancer Therapy

  2019cites this paper
• Risk Analysis for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving FEC100 Treatment

  2019cites this paper
• Breast Cancer

  2019cites this paper
• Concurrent Administration of Trastuzumab and Anthracycline for Breast Cancer Treatment: An Unassailable Contraindication?

  2018cites this paper
• Metastasis-free interval in breast cancer patients: Thirty-year trends and time dependency of prognostic factors. A retrospective analysis based on a single institution experience.

  2018cites this paper
• The efficacy of sodium azulene sulfonate L-glutamine for managing chemotherapy-induced oral mucositis in cancer patients: a prospective comparative study

  2018cites this paper
• Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study

  2018cites this paper
• Optimal time for adjuvant therapy initiation in breast cancer patients: A single center experience

  2018cites this paper
• Epirubicin‐loaded polymeric micelles effectively treat axillary lymph nodes metastasis of breast cancer through selective accumulation and pH‐triggered drug release

  2018cites this paper
• Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer

  2018cites this paper
• A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1).

  2018cites this paper
• Adjuvante Therapie bei Patientinnen mit Mammakarzinom

  2018cites this paper
• Quality of Life in Women With Breast Cancer Treated With or Without Chemotherapy

  2017cites this paper
• Survival and time to initiation of adjuvant chemotherapy among breast cancer patients: a systematic review and meta-analysis

  2017cites this paper
• The differential diagnosis of benign and malignant breast cancer using shear wave elastography (SWE)

  2017cites this paper
• Lentinula edodes mycelia extract plus adjuvant chemotherapy for breast cancer patients: Results of a randomized study on host quality of life and immune function improvement

  2017cites this paper
• Anthracycline vs Nonanthracycline Adjuvant Therapy for Breast Cancer

  2017cites this paper
• Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts

  2017cites this paper
• Fallo ovárico precoz quimioinducido en pacientes con cáncer de mama en edad reproductiva: valor pronóstico de los estimadores de reserva ovárica

  2017cites this paper
• Phase II study of neoadjuvant anthracycline combined with nanoparticle albumin-bound paclitaxel for human epidermal growth factor receptor 2-negative breast cancer.

  2017cites this paper
• Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without G-CSF in Locally Advanced Breast Cancer: Long-Term Results

  2017cites this paper
• On the Ontological Modelling of Co-medication and Drug Interactions in Medical Cancer Therapy Regimens for a Clinical Decision Support System

  2017cites this paper
• Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).

  2017cites this paper
• Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.

  2016cites this paper
• A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer.

  2016cites this paper
• The Results of Chemotherapy with Two Variants of Intravenous CMF in Patients with Early Stage Breast Carcinoma; Does Dose Density Matter?

  2016cites this paper
• Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment

  2016cites this paper
• Presenting features, treatment patterns and outcomes of patients with breast cancer in Pakistan: Experience at a university hospital.

  2016cites this paper
• Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study

  2015cites this paper
• Implicaciones pronósticas y terapéuticas del receptor del factor de crecimiento fibroblástico en pacientes con cáncer de mama metastásico

  2015cites this paper
• Clinical significance of locoregional and systemic treatment in operable high-risk breast cancer patients with more than four positive axillary lymph nodes

  2015cites this paper
• Progress in adjuvant chemotherapy for breast cancer: an overview

  2015cites this paper
• Fumarate Hydratase-deficient Cell Line NCCFH1 as a New In Vitro Model of Hereditary Papillary Renal Cell Carcinoma Type 2.

  2015cites this paper
• Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.

  2015cites this paper
• A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor ('SPROG' trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN.

  2015cites this paper
• Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia

  2015cites this paper
• 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial

  2015cites this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2015cites this paper
• SELECTING CHEMOTHERAPY SCHEDULES FOR ADJUVANT TREATMENT OF EARLY STAGE BREAST CANCER, WHAT IS THE RATIONALE BEHIND?

  2015cites this paper
• Sequential dose-dense 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel in patients with early breast cancer with four or more positive lymph nodes.

  2014cites this paper
• Breast cancer version 3.2014.

  2014cites this paper
• Utilisation of primary and secondary G-CSF prophylaxis enables maintenance of optimal dose delivery of standard adjuvant chemotherapy for early breast cancer: an analysis of 1655 patients.

  2014cites this paper
• Sequential Dose-dense 5-fluorouracil, Epirubicin and Cyclophosphamide Followed by Docetaxel in Patients with Early Breast Cancer with Four or more Positive Lymph Nodes

  2014cites this paper
• Adjuvant concurrent docetaxel, epirubicin and cyclophosphamide chemotherapy in breast cancer: The TEC regimen. A retrospective analysis

  2014cites this paper
• The Prophylactic Use of Filgrastim in Patients with Breast Cancer

  2013cites this paper
• Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia

  2013cites this paper
• Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.

  2013cites this paper
• Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.

  2013cites this paper
• Evaluation of host quality of life and immune function in breast cancer patients treated with combination of adjuvant chemotherapy and oral administration of Lentinula edodes mycelia extract

  2013cites this paper
• The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.

  2013cites this paper
• [Impact of taxanes in the adjuvant setting of node-negative breast cancers].

  2013cites this paper
• Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms

  2013cites this paper
• Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis

  2013cites this paper
• Complications following breast cancer therapy in the adult spina bifida population: A case report.

  2013cites this paper
• Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review

  2012cites this paper
• Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy

  2012cites this paper
• Achieving Optimal Dose Intensity with Adjuvant Chemotherapy in Elderly Breast Cancer Patients: A 10‐Year Retrospective Study in a UK Institution

  2012cites this paper
• Epirubicin: is it like doxorubicin in breast cancer? A clinical review.

  2012cites this paper
• MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide

  2012cites this paper
• [Short and medium term cardiotoxicity of anthracyclins: a prospective study].

  2012cites this paper
• Impact de l'obésité et de la composition corporelle sur la toxicité du Docetaxel : étude rétrospective sur 200 patientes traitées entre 2008 et 2010 au centre Henri Becquerel pour un cancer du sein localisé

  2012cites this paper
• Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.

  2012cites this paper
• Risk of treatment related death (TRD) with adjuvant chemotherapy for breast cancer: A study in University Malaya Medical Centre (UMMC)

  2012cites this paper
• Use of non‐anthracycline regimens in early stage breast cancer in Australia

  2011cites this paper
• Prise en charge préventive et curative des mucites du tractus digestif (mucites buccopharyngées, œsogastro-intestinales et anorectales)

  2011cites this paper
• Invasive breast cancer.

  2011cites this paper
• Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1

  2011cites this paper
• Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2011cites this paper
• Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma.

  2011cites this paper
• Pattern of care in locally advanced breast cancer: focus on local therapy.

  2011cites this paper
• High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer

  2011cites this paper
• Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results.

  2011cites this paper
• Chemotherapy for breast cancer (Review).

  2010cites this paper
• Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin’s lymphoma: single center, 15-year experience

  2010cites this paper
• Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan

  2010cites this paper
• [Pharmaceutical therapy of breast cancer].

  2010cites this paper
• Dose-rounding of adjuvant chemotherapy for breast cancer: an audit of toxicity

  2010cites this paper
• Breast cancer OncoGuia

  2010cites this paper
• [High risk of cardiac dysfunction after treatment of secondary acute myeloid leukemia following chemotherapy and radiotherapy for breast cancer].

  2010cites this paper
• Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated with Platinum-Doublet Chemotherapy

  2010cites this paper